黄芪总皂苷提取物对牛血清白蛋白致大鼠肝纤维化作用的影响

Effect of Astragalosides Extract on Liver Fibrosis Induced by Bovine Serum Albumin in Rats

摘要:

目的: 观察黄芪总皂苷提取物对牛血清白蛋白(BSA)致大鼠实验性肝纤维化作用的影响。 方法: 将60 只SD 大鼠随机分为正常对照组(A 组)、模型组(B 组)、秋水仙碱组(C 组)、黄芪总皂苷提取物低剂量组(D组)、黄芪总皂苷提取物中剂量组(E 组)、黄芪总皂苷提取物高剂量组(F 组),每组10 只。采用皮下多点注射牛血清白蛋白(BSA)免疫性诱导大鼠肝纤维化进行造模。造模后,C~F 组分别按0.1 mg·kg^-1·d^-1,15,30,60 mg·kg^-1·d^-1剂量ig 给药。55 d后,分别检测血清总蛋白(TP)、白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)及Ⅳ型胶原(Ⅳ-C)的含量,并对肝组织进行病理学观察。 结果: 黄芪总皂苷提取物可使BSA免疫性诱导的肝组织纤维增生、变性和坏死明显减轻。黄芪总皂苷提取物各组大鼠血清ALT,AST,HA,LN,PC-Ⅲ,Ⅳ-C及肝组织羟脯氨酸含量与模型组比较均显著降低(P<0.05, P<0.01)。病理组织学观测结果显示,黄芪总皂苷各剂量组与模型组比较均有不同程度改善。 结论: 黄芪总皂苷对BSA所致实验性大鼠肝纤维化具有良好的治疗作用。

Abstract:

Objective: To observe effect of astragalosides extract on liver fibrosis in rats. Method: Sixty SD rats were randomly divided into six groups: normal control group (A), model group (B), colchicine group(C),low-dose astragalosides group(D),middle-dose astragalosides group (E) and high-dose astragalosides group (F).Liver fibrosis model in rat was produced with bovine serum albumin(ABS). Group C received colchicine (0.1 mg·kg^-1·d^-1);group D,E, F received low-dose astragalosides (15 mg·kg^-1·d^-1), middle-dose astragalosides (30 mg·kg^-1·d^-1) and high-dose astragalosides (60 mg·kg^-1·d^-1) ig respectively. After 55 days, serum levels of serum total protein (TP), albumin(ALB),alanine aminotransferase(ALT),aspartate aminotransferase(AST),hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(PC-Ⅲ) and type Ⅳ collagen (Ⅳ-C) in different groups were detected. Result: Compared with model group,levels of ALT,AST,HA,LN,PC-Ⅲand Ⅳ-C in the treatment groups were obviously improved.It had significantly statistical difference(P<0.05, P<0.01).Pathological result showed that the liver fibrosis in the treatment groups was signiflcantly attanuated. Conclusion: These results suggested that astragalosides shows obvious effect against rat hepatic fibrosis.